Apixaban Market

≥99.5% represents 68.2% of purity grade sales and generic pharmaceutical manufacturers account for 66.4% within the buyer type segment in 2026. The apixaban market is estimated at USD 372.28 million in 2026, is projected to reach USD 973.64 million by 2036 and is forecast to post a 10.1% CAGR between 2026 and 2036.